Ph.D., CEO and CSO, C2i Genomics
Biography
Dr. Asaf Zviran brings 15+ years of R&D management in biology and defense.To date he has managed to publish 13 papers with over 1,700 citations (including Nature and Stem Cell). Asaf received multiple awards and grants. He is an IDF R&D Officer (Captain) with a PhD in Molecular Biology.
Clinical Dx Showcase:
C2i Genomics
C2i Genomics is the first company to develop post-surgery monitoring of cancer recurrence and progression by analyzing subtle changes in the pattern of the tumor’s DNA.
C2i’s Cancer Recognition for Personalized Treatment Monitoring
C2i’s SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging low-input blood (only 2mL blood) whole-genome sequencing to provide high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development.
Session Abstract – PMWC 2022 Silicon Valley
Track 6 - June 28 9.00 A.M.-4.45 P.M.,Track 6 - June 29 3.30 P.M.-3.45 P.M.,Track 6 - June 30 9.00 A.M.-1.15 P.M.
The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative
